Brief: Amylyx Pharma Announces First Participant Dosed In Phase 1, Multiple Ascending Dose Lumina Trial Of Amx0114 In People Living With Amyotrophic Lateral Sclerosis
09/04/2025 12:01
April 9 (Reuters) - Amylyx Pharmaceuticals Inc AMLX.O: AMYLYX PHARMACEUTICALS ANNOUNCES FIRST PARTICIPANT DOSED IN PHASE 1, MULTIPLE ASCENDING DOSE LUMINA TRIAL OF AMX0114 IN PEOPLE LIVING WITH AMYOTROPHIC LATERAL SCLEROSIS AMYLYX PHARMACEUTICALS INC: AMYLYX EXPECTS EARLY COHORT DATA FROM LUMINA THIS YEAR Source text: ID:nBw8x7L5Wa Further company coverage: AMLX.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Amylyx Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-LSI Industries, SiTime, Andersen Group
U.S. STOCKS ON THE MOVE-Apple, Hims & Hers Health, Sysco
U.S. STOCKS ON THE MOVE-Nordson, Nebius, Deere
Amylyx dips after increased $500 mln stock sale to fund blood sugar drug
Brief: Amylyx Pharmaceuticals Announces Pricing Of Upsized $500 Million Underwritten Public Offering Of Common Stock